Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.
作者信息
Xie Hao, Adjei Alex A
机构信息
Mayo Clinic, Rochester, MN, USA.
出版信息
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S41-S43. doi: 10.21037/tlcr.2017.10.15.
Abstract
摘要
相似文献
1
Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.阿维鲁单抗：非小细胞肺癌中的另一种活性免疫检查点抑制剂。
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S41-S43. doi: 10.21037/tlcr.2017.10.15.
2
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.多次给予抗 PD-L1 人源 IgG1 单克隆抗体avelumab 后的外周免疫组分析。
J Immunother Cancer. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y. eCollection 2017.
3
A review of avelumab in locally advanced and metastatic bladder cancer.阿维鲁单抗治疗局部晚期和转移性膀胱癌的综述。
Ther Adv Urol. 2019 Jan 30;11:1756287218823485. doi: 10.1177/1756287218823485. eCollection 2019 Jan-Dec.
4
Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.免疫检查点抑制剂在非小细胞肺癌中的应用：鸟瞰全局。
Life Sci. 2019 Sep 15;233:116713. doi: 10.1016/j.lfs.2019.116713. Epub 2019 Aug 3.
5
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.晚期肺癌中不断演变的免疫肿瘤格局：非小细胞肺癌的一线治疗
Ther Adv Med Oncol. 2019 Aug 28;11:1758835919870360. doi: 10.1177/1758835919870360. eCollection 2019.
6
Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma.阿维鲁单抗治疗转移性默克尔细胞癌期间因结节病导致的高钙血症
Case Rep Oncol. 2019 Aug 8;12(2):639-643. doi: 10.1159/000502285. eCollection 2019 May-Aug.
7
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.阿维鲁单抗用于既往接受过治疗的转移性或复发性非小细胞肺癌患者（JAVELIN实体瘤研究）：一项多中心、开放标签的1b期试验的剂量扩展队列研究
Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub 2017 Mar 31.
8
Avelumab: a new standard for treating metastatic Merkel cell carcinoma.阿维鲁单抗：治疗转移性 Merkel 细胞癌的新标准。
Expert Rev Anticancer Ther. 2018 Apr;18(4):319-326. doi: 10.1080/14737140.2018.1445528. Epub 2018 Feb 28.
9
Avelumab: A Review in Metastatic Merkel Cell Carcinoma.avelumab：转移性 Merkel 细胞癌的治疗药物评价。
Target Oncol. 2018 Jun;13(3):409-416. doi: 10.1007/s11523-018-0571-4.
10
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.采用新型抗PD-L1抗体阿维鲁单抗通过抗体依赖性细胞介导的细胞毒性增强对脊索瘤细胞的杀伤作用。
Oncotarget. 2016 Jun 7;7(23):33498-511. doi: 10.18632/oncotarget.9256.
引用本文的文献
1
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.单克隆抗体在非小细胞肺癌中的治疗综述。
Adv Exp Med Biol. 2021;1286:49-64. doi: 10.1007/978-3-030-55035-6_3.
2
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.基于 PD-1/PD-L1 通路抑制剂的免疫疗法在卵巢癌治疗中的应用。
Clin Exp Immunol. 2019 Mar;195(3):334-344. doi: 10.1111/cei.13255. Epub 2019 Jan 21.
本文引用的文献
1
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).阿特珠单抗作为程序性死亡配体1筛选的晚期非小细胞肺癌患者一线或后续治疗的II期试验（BIRCH）
J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.
2
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.阿维鲁单抗用于治疗转移性或局部晚期经治实体瘤（JAVELIN实体瘤研究）：一项1a期、多队列、剂量递增试验
Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.
3
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.阿维鲁单抗用于既往接受过治疗的转移性或复发性非小细胞肺癌患者（JAVELIN实体瘤研究）：一项多中心、开放标签的1b期试验的剂量扩展队列研究
Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub 2017 Mar 31.
4
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
5
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
6
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
7
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
8
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.阿维鲁单抗治疗化疗难治性转移性默克尔细胞癌患者：一项多中心、单组、开放标签的2期试验。
Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.
9
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
10
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Zotero 插件